Diffusion Pharmaceuticals LLC   Report issue

For profit Phase 2 Phase 3
Founded: Charlottesville VA United States (2001)

Organization Overview

First Clinical Trial
2008
NCT00725881
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Diffusion Pharmaceuticals Inc

Active Ingredients

Drugs in Phase 3 Trials (2)

temozolomide (temodar) (1 trial)

trans sodium crocetinate (9 trials)

Drugs in Phase 2 Trials (3)

Key: Diffusion Pharmaceuticals LLC (1) Acquired (2)

neflamapimod (3 trials)

sodium chloride (1 trial)

vx-745 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 3)

Glioma (Phase 2)

Intermittent Claudication (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 5